KFO 286 – 
Exploiting defects in the DNA damage response for the development of novel, targeted CLL therapy

 The Clinical Research Unit (KFO)-286 "Exploiting defects in the DNA damage response for the development of novel, targeted CLL therapy" is an interdisciplinary, cross faculty research center of excellence funded through the Deutsche Forschungsgemeinschaft (DFG). 

 The overarching goal of the KFO-286 is to unravel the molecular alterations that lead to the development of chronic lymphocytic leukemia (CLL). A specific focus will be set on molecular defects in the DNA damage response signaling network, as CLLs with aberrant DNA damage signaling frequently display robust resistance against frontline chemotherapy. It is the declared goal of this research consortium to exploit our molecular understanding of this disease to uncover molecular liabilities that are specific to CLL cells and can thus be therapeutically exploited. Through the integration of numerous physician scientists into our consortium, we will be able to directly pursue translational aspects of our research.

 The Clinical Research Unit-286 started its second funding period in November 2016 and is organized into 7 scientific and 2 central projects. The speaker of the CRU is Professor Michael Hallek, director of the Clinic I of Internal Medicine of the University Hospital of Cologne. The scientific coordinator of the CRU is Professor Christian Reinhardt, Clinic I of Internal Medicine of the University Hospital of Cologne.